Literature DB >> 16445376

Surgical options and outcomes in bone sarcoma.

Hazem Wafa1, Robert J Grimer.   

Abstract

Bone sarcomas are challenging to treat. The primary goal of treatment is local control of the disease while, if possible, achieving salvage of the limb and its function. There is no ideal method of reconstruction in limb-salvage surgery but the choice of the method of reconstruction should be individualized based upon many factors including the patient's age, the extent and location of the tumor, the wishes of the patient, and the availability of surgical facilities and expertise, as well as the cost of the procedure. In this review, the authors explore the advantages and disadvantages of the different methods of limb reconstruction. The surgical management of bone sarcomas is a real challenge to the orthopedic surgeon, owing to the diversity of sites in which tumors arise, combined with the extension of the tumor into adjacent soft tissues and their proximity, in many cases, to major neurovascular structures. There have been dramatic improvements in survival for patients with osteosarcoma and Ewing's sarcoma in the past 30 years owing to increasing effectiveness of chemotherapy. This, along with developments in imaging techniques (magnetic resonance imaging in particular) has led to earlier diagnosis and more accurate preoperative staging. Whilst traditional treatment for bone tumors used to be amputation, advances in surgical techniques have made limb-salvage procedures a valid alternative method of treatment to amputation in 80-85% of patients with primary bone sarcomas.

Entities:  

Mesh:

Year:  2006        PMID: 16445376     DOI: 10.1586/14737140.6.2.239

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  21 in total

1.  Trends in presentation of bone and soft tissue sarcomas over 25 years: little evidence of earlier diagnosis.

Authors:  G M Smith; G D Johnson; R J Grimer; S Wilson
Journal:  Ann R Coll Surg Engl       Date:  2011-10       Impact factor: 1.891

2.  Genetic variations in the PRKCG gene and osteosarcoma risk in a Chinese population: a case-control study.

Authors:  Huading Lu; Lei Zhu; Liyi Lian; Mingwei Chen; Dehai Shi; Kun Wang
Journal:  Tumour Biol       Date:  2015-02-09

3.  Image-guided musculoskeletal biopsies.

Authors:  Huy B Q Le; Steven T Lee; Peter L Munk
Journal:  Semin Intervent Radiol       Date:  2010-06       Impact factor: 1.513

4.  [Proximal tibial replacement and alloplastic reconstruction of the extensor mechanism after bone tumor resection].

Authors:  B M Holzapfel; H Pilge; A Toepfer; R G Jakubietz; H Gollwitzer; H Rechl; R von Eisenhart-Rothe; M Rudert
Journal:  Oper Orthop Traumatol       Date:  2012-07       Impact factor: 1.154

5.  6-Gingerol inhibits osteosarcoma cell proliferation through apoptosis and AMPK activation.

Authors:  Jingzhang Fan; Xin Yang; Zhenggang Bi
Journal:  Tumour Biol       Date:  2014-10-21

6.  Aurora B kinase as a novel molecular target for inhibition the growth of osteosarcoma.

Authors:  Zhenjiang Zhao; Guoguo Jin; Ke Yao; Kangdong Liu; Fangfang Liu; Hanyong Chen; Keke Wang; Dhilli Rao Gorja; Kanamata Reddy; Ann M Bode; Zhiping Guo; Zigang Dong
Journal:  Mol Carcinog       Date:  2019-03-01       Impact factor: 4.784

7.  Can a Bayesian Belief Network Be Used to Estimate 1-year Survival in Patients With Bone Sarcomas?

Authors:  Rajpal Nandra; Michael Parry; Jonathan Forsberg; Robert Grimer
Journal:  Clin Orthop Relat Res       Date:  2017-04-10       Impact factor: 4.176

8.  Acriflavine suppresses the growth of human osteosarcoma cells through apoptosis and autophagy.

Authors:  Jingzhang Fan; Xin Yang; Zhenggang Bi
Journal:  Tumour Biol       Date:  2014-06-25

9.  Single-nucleotide polymorphisms of the PRKCG gene and osteosarcoma susceptibility.

Authors:  Ying Zhang; Xu Hu; Hong-Kai Wang; Wei-Wei Shen; Tong-Quan Liao; Pei Chen; Tong-Wei Chu
Journal:  Tumour Biol       Date:  2014-09-25

10.  Nonreferral of possible soft tissue sarcomas in adults: a dangerous omission in policy.

Authors:  Juan F Abellan; José M Lamo de Espinosa; Julio Duart; Ana Patiño-García; Salvador Martin-Algarra; Rafael Martínez-Monge; Mikel San-Julian
Journal:  Sarcoma       Date:  2009-12-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.